Logo
Aessoa Ultra with Lidocaine (1x1ml)

Aessoa Ultra with Lidocaine (1x1ml)

Aessoa

Dermal Filler
  • CE Marked hyaluronic acid dermal filler / medical device.
  • Manufactured under Good Manufacturing Practice (GMP).
  • Produced within an ISO 13485 Compliant quality management system for medical devices.
  • Professional Use Only product; supply and use subject to local medical and aesthetic regulations.
Hyaluronic Acid Volumising Dermal Filler with Lidocaine

Description

Aessoa Ultra with Lidocaine (1x1ml) is a high-viscosity, monophasic cross-linked hyaluronic acid dermal filler developed by Oreon Life Science for deep wrinkle correction, volume restoration, and facial contouring. As one of the thickest fillers in the Aessoa range, it is formulated with 24 mg/ml hyaluronic acid and 3 mg/ml lidocaine (0.3%) to provide strong lifting capacity, structural support, and enhanced patient comfort. The smooth, cohesive gel is designed for injection into the subcutaneous or mid-to-deep dermis, where it can sculpt and define areas such as the cheeks, chin, jawline, nose, and deep nasolabial folds. Aessoa Ultra delivers natural-looking volume and long-lasting results that typically extend up to around 12 months, with some reports of longevity up to 18 months depending on patient and treatment factors.

Bnefits

  • Provides strong volumising and lifting effects for midface and lower-face areas.
  • Smooth, cohesive gel structure allows precise contouring and definition of facial features.
  • Effectively treats deep wrinkles and severe folds, including nasolabial and marionette lines.
  • Restores lost volume in the cheeks, chin, and jawline for a more sculpted appearance.
  • Suitable for non-surgical reshaping of the nose in appropriately selected patients.
  • High viscoelasticity and cohesiveness help the filler act like an implant, maintaining shape and projection.
  • Integrated lidocaine (0.3%) minimises discomfort during injection and improves treatment tolerability.
  • Monophasic cross-linked hyaluronic acid formulation supports natural-looking, uniform results.
  • Clinical effect commonly lasts around 9–12 months, with some cases reported up to 18 months depending on area, technique, and patient metabolism.
  • Designed for professional use, giving experienced injectors a versatile tool for deep wrinkle correction and structural contouring.

Indications

  • Correction of deep facial wrinkles and severe folds.
  • Treatment of deep nasolabial folds (smile lines).
  • Treatment of marionette lines and other deep perioral folds.
  • Volume restoration and contouring of the cheeks.
  • Chin augmentation and projection.
  • Jawline contouring and definition.
  • Non-surgical nasal contouring (rhinoplasty) in suitable candidates.
  • General facial volumetry and contour correction in subcutaneous or mid-to-deep dermal planes.
  • Selected body contouring indications where a high-viscosity hyaluronic acid filler is appropriate, as per practitioner judgment and local regulations.

Composition

  • Monophasic cross-linked hyaluronic acid (HA): 24 mg/ml.
  • Lidocaine hydrochloride: 3 mg/ml (0.3%) as a local anaesthetic.
  • Physiological buffer solution and excipients (q.s.), as specified in the manufacturer’s instructions for use.

Formulation

  • High-viscosity, monophasic, cross-linked hyaluronic acid gel with lidocaine.
  • Designed for subcutaneous and mid-to-deep dermal injection for volume and contouring.
  • High cohesiveness and hardness so the filler behaves like an implant and maintains structure at the injection site.
  • High viscoelasticity (complex viscosity often described in the 300–500 Pa·s range) to support effective moulding and projection.
  • Sterile, pyrogen-free, non-animal-derived hyaluronic acid formulation.

Packaging

  • Box containing 1 x 1 ml pre-filled glass syringe of Aessoa Ultra with Lidocaine.
  • Some distributors supply only the pre-filled syringe (no needles included), with a 25G needle commonly recommended.
  • Other distributors supply 1 x 1 ml syringe plus 2 x 25G needles in the pack.
  • Syringe equipped with a Luer-lock connection compatible with standard needles and cannulas.
  • Each syringe/blister is individually sterile-packed within an outer carton labelled with product name, batch number, and expiry date.
  • Single-use, sterile medical device intended exclusively for professional use.

Usage

  • For professional use only; injections must be performed by appropriately trained and licensed healthcare practitioners experienced in facial anatomy and dermal filler procedures.
  • Before treatment, obtain a complete medical history, assess indications and contraindications, and agree on realistic expectations with the patient; obtain informed consent in accordance with local regulations.
  • Cleanse and disinfect the treatment area thoroughly using an appropriate antiseptic solution prior to injection.
  • Aessoa Ultra is generally injected into the subcutaneous or mid-to-deep dermal layer, depending on the indication, area, and technique.
  • Use an appropriate needle (commonly 25G) or microcannula in line with manufacturer/distributor recommendations and practitioner preference.
  • Inject slowly with controlled, steady pressure, regularly aspirating as appropriate and adhering to safe injection practices to minimise the risk of intravascular injection.
  • Apply suitable injection techniques (e.g. linear threading, fanning, depot/bolus injections) according to the anatomical area and desired outcome.
  • Avoid overcorrection, bearing in mind initial swelling and the hydrophilic nature of hyaluronic acid when determining volume.
  • After injection, gently mould and contour the product with light massage if required to ensure smooth, even distribution and harmonious facial contours.
  • Advise standard post-treatment care: avoid makeup on treated areas for several hours; avoid extreme temperatures, strenuous exercise, and alcohol for 24 hours; and avoid facials or energy-based treatments over the treated area for the period recommended by the practitioner.
  • Schedule a follow-up appointment, typically after 2–4 weeks, to assess the outcome and determine whether any touch-up treatment is needed.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid.
  • Known hypersensitivity or allergy to lidocaine or other amide-type local anaesthetics.
  • History of severe allergic reactions or anaphylaxis to injectable fillers or any component of the product.
  • Active skin infections, inflammatory conditions, or lesions (e.g. acne, herpes, dermatitis) at or near the intended injection sites.
  • Current systemic infections or uncontrolled systemic diseases where elective injectable treatment may pose additional risk, according to clinician judgment.
  • Patients with known bleeding disorders or those receiving significant anticoagulant or antiplatelet therapy where the risk of bleeding or haematoma is unacceptable, unless carefully assessed and managed by the prescribing clinician.
  • Pregnant or breastfeeding patients (use is generally not recommended due to lack of adequate safety data).
  • Patients under 18 years of age or below the legal minimum age for aesthetic procedures in the relevant jurisdiction.
  • Injection into or near vascular structures; intravascular injection is strictly contraindicated.
  • Use in areas with compromised tissue viability, severe scarring, or permanent implants, unless carefully evaluated and deemed appropriate by the treating practitioner.

Adverse Effects

  • Common, generally transient local reactions at injection sites such as redness, swelling, tenderness, pain, itching, bruising, and induration.
  • Oedema or puffiness in the treated area, particularly in more vascular regions, generally resolving spontaneously within days.
  • Small lumps or nodules at or near the injection site, usually resolving with massage or conservative management.
  • Temporary asymmetry or irregular contours related to injection technique or post-treatment swelling.
  • Inflammatory or hypersensitivity reactions including prolonged swelling, firmness, or delayed inflammatory nodules (rare).
  • Infection at the injection site if aseptic technique is not strictly followed (rare).
  • Rare but serious complications associated with hyaluronic acid fillers, including vascular occlusion, tissue ischaemia, and potential tissue necrosis when product is inadvertently injected into or compresses a blood vessel.
  • Very rare risk of visual disturbance or blindness if inadvertent intravascular injection occurs in high-risk facial vascular territories.
  • Any persistent, severe, or unexpected adverse event should be promptly evaluated and managed according to local clinical protocols, which may include the use of hyaluronidase and/or urgent referral.

Storage Conditions

  • Store at a controlled temperature in accordance with the manufacturer’s recommendations (typically between 2°C and 25°C).
  • Protect from direct sunlight and excessive heat or humidity.
  • Do not freeze the product.
  • Keep the syringe in its original sterile blister and outer carton until immediately before use.
  • Do not use the product after the expiry date indicated on the packaging.
  • Do not use if the sterile blister or outer packaging is damaged or has been previously opened.
  • Store out of the reach of children and unauthorised persons.

Duration

Results typically last around 9\u201312 months, with some sources and clinical experience indicating potential longevity up to approximately 18 months depending on treatment area, injection technique, product volume, and individual patient factors such as metabolism and lifestyle.

Onset

Visible volume restoration and contouring are usually immediate after injection, with final results becoming more apparent over several days as initial swelling and minor injection-related reactions subside.

Browse more Dermal Filler

Top Treatments

Top Cities in the UK